Patent classifications
C07D241/14
Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) ##STR00001##
wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of
##STR00001##
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of
##STR00001##
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
CGRP RECEPTOR ANTAGONISTS
The disclosures herein relate to novel compounds of formula
##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP RECEPTOR ANTAGONISTS
The disclosures herein relate to novel compounds of formula
##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP receptor antagonists
The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP receptor antagonists
The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KB INHIBITORS
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I)
##STR00001##
wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF VANIN-1 ENZYME
Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
##STR00001##
Drug-conjugates, conjugation methods, and uses thereof
In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.